Pharmacology of renal endothelin receptors

Endothelin in Renal Physiology and Disease

Volumn 172, Issue , 2011, Pages 1-17

  Davenport, Anthony P ^a   Maguire, Janet J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926077400     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000328678     Document Type: Chapter

References (59)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
2. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348:730-732.
3. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T: Cloning of a cDNA encoding a nonisopeptide-selective subtype of the endothelin receptor. Nature 1990;348:732-735.
4. Davenport AP: International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature. Pharmacol Rev 2002;54:219-226.
5. Davenport AP, Maguire JJ: Endothelin. Handbk Exp Pharmacol 2006;176:295-329.
6. Karet FE, Davenport AP: Localization of endothelin peptides in human kidney. Kidney Int 1996;49:382-387.
7. Ong AC, Jowett TP, Firth JD, Burton S, Karet FE, Fine LG: An endothelin-1 mediated autocrine growth loop involved in human renal tubular regeneration. Kidney Int 1995;48:390-401.
8. Kuc R, Davenport AP: Comparison of endothelin-A and endothelin-B receptor distribution visualized by radioligand binding versus immunocytochemical localization using subtype selective antisera. J Cardiovasc Pharmacol 2004;44(Suppl 1):S224-S226.
9. Herman WH, Emancipator SN, Rhoten RL, Simonson MS: Vascular and glomerular expression of endothelin-1 in normal human kidney. Am J Physiol 1998;275:F8-F17.
10. Morigi M, Buelli S, Angioletti S, Zanchi C, Longaretti L, Zoja C, Galbusera M, Gastoldi S, Mundel P, Remuzzi G, Benigni A: In response to protein load podocytes reorganize cytoskeleton and modulate endothelin-1 gene: implication for permselective dysfunction of chronic nephropathies. Am J Pathol 2005;166:1309-1320.
11. Gauquelin G, Thibault G, Garcia R:Characterization of renal glomerular endothelin receptors in the rat. Biochem Biophys Res Commun 1989;164:54-57.
12. Rebibou JM, He CJ, Delarue F, Peraldi MN, Adida C, Rondeau E, Sraer JD: Functional endothelin 1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant 1992;7:288-292.
13. Ortmann J, Amann K, Brandes RP, Kretzler M, Munter K, Parekh N, Traupe T, Lange M, Lattmann T, Barton M: Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004;44:9749-9781.
14. Barton M: Reversal of proteinuric renal disease and the emerging role of endothelin. Nat Clin Pract Nephrol 2008;4:490-501.
15. Barton M: Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans. Biochim Biophys Acta 2010;1802:1203-1213.
16. Neuhofer W, Pittrow D: Endothelin receptor selectivity in chronic kidney disease:rationale and review of recent evidence. Eur J Clin Invest 2009;39(Suppl 2):50-67.
17. Vachiery JL, Davenport A: The endothelin system in pulmonary and renal vasculopathy:les liaisons dangereuses. Eur Respir Rev 2009;18:260-271.
18. Kohan DE: The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure. Curr Opin Nephrol Hypertens 2006;15:34-40.
19. Kohan DE, Rossi NF, Inscho EW, Pollock DM: Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 2011;91:1-77.
20. Karet FE, Kuc RE, Davenport AP: Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int 1993;44:36-42.
21. Palmer MJ: Endothelin receptor antagonists:status and learning 20 years on. Prog Med Chem 2009;47:203-37.
22. Maguire JJ, Davenport AP: Importance of sub-type selectivity for endothelin receptor antagonists in the human vasculature; in Handler C, Abraham D, Dashwood M, Coghlan G, (eds): Translational Vascular Medicine: Pathogenesis, Diagnosis, and Treatment. Berlin, Springer, 2011, pp 1-34.
23. Barst RJ, Langleben D, Badesch D, Frost A, Lawrence EC, Shapiro S, Naeije R, Galie N:Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-2056.
24. Haynes WG, Webb DJ: Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344:852-854.
25. Davenport AP, O'Reilly G, Kuc RE:Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA subtype. Br J Pharmacol 1995;114:1110-1116.
26. Kuc RE, Karet FE, Davenport AP:Characterization of peptide and nonpeptide antagonists in human kidney. J Cardiovasc Pharmacol 1995;26(Suppl 3):S373-S375.
27. Maguire JJ, Kuc RE, O'Reilly G, Davenport AP: Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro. Br J Pharmacol 1994;113:49-54.
28. Davenport AP, Kuc RE, Hoskins SL, Karet FE, Fitzgerald F: [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature. Br J Pharmacol 1994;113:1303-1310.
29. Maguire JJ, Davenport AP: ETA receptormediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol 1995;115:191-197.
30. Matsuura T, Miura K, Ebara T, Yukimura T, Yamanaka S, Kim S Iwao H: Renal vascular effects of the selective endothelin receptor antagonists in anaesthetized rats. Br J Pharmacol 1997;122:81-86.
31. Kiowski W, Luscher TF, Linder L, Buhler FR: Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 1991;83:469-475.
32. Love MP, Ferro CJ, Haynes WG, et al:Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc Res 2000;47:166-172.
33. Strachan FE, Spratt JC, Wilkinson IB, Johnston NR, Gray GA, Webb DJ: Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension 1999;33:581-585.
34. Montanari A, Biggi A, Carra N, Fasoli E, Calzolari M, Corsini F, Perinotto P, Novarini A: Endothelin-A blockade attenuates systemic and renal hemodynamic effects of L-NAME in humans. Hypertension 2000;35:518-23.
35. Bohm F, Pernow J, Lindstrom J, Ahlborg G: ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond) 2003;104:143-151.
36. Kaasjager KA, Shaw S, Koomans HA, Rabelink TJ: Role of endothelin receptor subtypes in the systemic and renal responses to endothelin-1 in humans. J Am Soc Nephrol 1997;8:32-39.
37. Widmer CC, Mundy AL, Kretz M, Barton M: Marked heterogeneity of endothelinmediated contractility and contraction dynamics in mouse renal and femoral arteries. Exp Biol Med (Maywood) 2006;231:777-781.
38. Simchon S, Manger WM, Carlin RD, Peeters LL, Rodriguez J, Batista D, Brown T, Merchant NB, Jan KM, Chien S: Saltinduced hypertension in Dahl salt-sensitive rats. Hemodynamics and renal responses. Hypertension 1989;13:612-621.
39. Barton M, Vos I, Shaw S, Boer P, D'Uscio LV, Grone HJ, Rabelink TJ, Lattmann T, Moreau P, Luscher TF: Dysfunctional renal nitric oxide synthase as a determinant of salt-sensitive hypertension: mechanisms of renal artery endothelial dysfunction and role of endothelin for vascular hypertrophy and Glomerulosclerosis. J Am Soc Nephrol 2000;11:835-845.
40. Schroeder AC, Imig JD, LeBlanc EA, Pham BT, Pollock DM, Inscho EW: Endothelinmediated calcium signaling in preglomerular smooth muscle cells. Hypertension 2000;35:280-286.
41. Betts LC, Kozlowski RZ: Electrophysiological effects of endothelin-1 and their relationship to contraction in rat renal arterial smooth muscle. Br J Pharmacol 2000;130:787-796.
42. Thai TL, Arendshorst WJ: ADP-ribosyl cyclase and ryanodine receptors mediate endothelin ETA and ETB receptor-induced renal vasoconstriction in vivo. Curr Opin Nephrol Hypertens 2009;18:40-49.
43. Schildroth J, Rettig-Zimmermann J, Kalk P, et al: Endothelin type A and B receptors in the control of afferent and efferent arterioles in mice. Nephrol Dial Transplant. Am J Physiol Renal Physiol 2008;295:F360-F368.
44. Ong AC, Newby LJ, Dashwood MR:Expression and cellular localisation of renal endothelin-1 and endothelin receptor subtypes in autosomal-dominant polycystic kidney disease (abstract). Nephron Exp Nephrol 2003;93:e80.
45. Maguire JJ, Davenport AP: No alteration in vasoconstrictor endothelin-B-receptor density or function in human coronary artery disease. J Cardiovasc Pharmacol 2000;36:S380-S381.
46. Ohkita M, Takaoka M, Matsumura Y:Drug discovery for overcoming chronic kidney disease (CKD): the endothelin ET B receptor/nitric oxide system functions as a protective factor in CKD. J Pharmacol Sci 2009;109:7-13
47. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M: Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994;199:1461-1465.
48. Gasic S, Wagner OF, Vierhapper H, Nowotny P, Waldhausl W: Regional hemodynamic effects and clearance of endothelin-1 in humans: renal and peripheral tissues may contribute to the overall disposal of the peptide. J Cardiovasc Pharmacol 1992;19:176-180.
49. Pumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP: The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol 1996;119:311-314.
50. Johnstrom P, Fryer TD, Richards HK, et al: Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ET B receptors in vivo. Br J Pharmacol 2005;144:115-122.
51. Johnstrom P, Fryer TD, Richards HK, Maguire JJ, Clark JC, Pickard JD, Davenport AP: Positron emission tomography of [18F]-big endothelin-1 reveals renal excretion but tissue-specific conversion to [18F]-endothelin-1 in lung and liver. Br J Pharmacol;159:812-819.
52. Kelland NF, Kuc RE, McLean DL, Azfer A, Bagnall AJ, Gray GA, Gulliver-Sloan FH, Maguire JJ, Davenport AP, Kotelevtsev YV, Webb DJ: Endothelial cell-specific ETB receptor knockout: autoradiographic and histological characterisation and crucial role in the clearance of endothelin-1. Can J Physiol Pharmacol;88:644-651.
53. Bagnall AJ, Kelland NF, Gulliver-Sloan F, Davenport AP, Gray GA, Yanagisawa M, Webb DJ, Kotelevtsev YV: Deletion of endothelial cell endothelin B receptors does not affect blood pressure or sensitivity to salt. Hypertension 2006;48:286-293.
54. Dhaun N, Ferro CJ, Davenport AP, Haynes WG, Goddard J, Webb DJ: Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 2007;22:3228-3234.
55. Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, Webb DJ: Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004;109:1186-1193.
56. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ: Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 2009;54:113-119.
57. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G: Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21:527-535.
58. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL:Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011;22:763-772.
59. Reriani M, Raichlin E, Prasad A, Mathew V, Pumper GM, Nelson RE, Lennon R, Rihal C, Lerman LO, Lerman A: Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis. Circulation 2010;122:958-966.